Virus de la fièvre jaune : Questions médicales fréquentes
Nom anglais: Yellow fever virus
Descriptor UI:D015005
Tree Number:B04.820.578.344.350.990
Termes MeSH sélectionnés :
Randomized Controlled Trials as Topic
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Virus de la fièvre jaune : Questions médicales les plus fréquentes",
"headline": "Virus de la fièvre jaune : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Virus de la fièvre jaune : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-17",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Virus de la fièvre jaune"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Flavivirus",
"url": "https://questionsmedicales.fr/mesh/D005416",
"about": {
"@type": "MedicalCondition",
"name": "Flavivirus",
"code": {
"@type": "MedicalCode",
"code": "D005416",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.820.578.344.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Virus de la fièvre jaune",
"alternateName": "Yellow fever virus",
"code": {
"@type": "MedicalCode",
"code": "D015005",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Betânia Paiva Drumond",
"url": "https://questionsmedicales.fr/author/Bet%C3%A2nia%20Paiva%20Drumond",
"affiliation": {
"@type": "Organization",
"name": "Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil."
}
},
{
"@type": "Person",
"name": "Marta Giovanetti",
"url": "https://questionsmedicales.fr/author/Marta%20Giovanetti",
"affiliation": {
"@type": "Organization",
"name": "Laboratório de Flavivírus, Instituto Oswaldo Cruz Fiocruz, Rio de Janeiro, Brazil giovanetti.marta@gmail.com."
}
},
{
"@type": "Person",
"name": "Pedro Augusto Alves",
"url": "https://questionsmedicales.fr/author/Pedro%20Augusto%20Alves",
"affiliation": {
"@type": "Organization",
"name": "Instituto René Rachou/Fundação Oswaldo Cruz, 30190-002 Belo Horizonte, Minas Gerais, Brazil."
}
},
{
"@type": "Person",
"name": "Matheus Soares Arruda",
"url": "https://questionsmedicales.fr/author/Matheus%20Soares%20Arruda",
"affiliation": {
"@type": "Organization",
"name": "Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil."
}
},
{
"@type": "Person",
"name": "Gabriela Fernanda Garcia Oliveira",
"url": "https://questionsmedicales.fr/author/Gabriela%20Fernanda%20Garcia%20Oliveira",
"affiliation": {
"@type": "Organization",
"name": "Departament of Microbiology, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, Minas Gerais, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A randomized controlled trial evaluating the effects of motivational interviewing in new hearing aid users (MI-HAT): study protocol for a randomized controlled trial.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37217960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-023-07352-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Protocol for a randomized controlled trial: exercise-priming of CBT for depression (the CBT+ trial).",
"datePublished": "2024-10-07",
"url": "https://questionsmedicales.fr/article/39375728",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08495-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Understanding explanatory and pragmatic trials: Examples from randomized controlled trials on vertebroplasty.",
"datePublished": "2022-12-23",
"url": "https://questionsmedicales.fr/article/36566693",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neuchi.2022.101403"
}
},
{
"@type": "ScholarlyArticle",
"name": "Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.",
"datePublished": "2023-01-22",
"url": "https://questionsmedicales.fr/article/36606735",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cpt.2841"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35804404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06365-y"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Virus",
"item": "https://questionsmedicales.fr/mesh/D014780"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012328"
},
{
"@type": "ListItem",
"position": 4,
"name": "Virus à ARN à brin positif",
"item": "https://questionsmedicales.fr/mesh/D000085102"
},
{
"@type": "ListItem",
"position": 5,
"name": "Flaviviridae",
"item": "https://questionsmedicales.fr/mesh/D018067"
},
{
"@type": "ListItem",
"position": 6,
"name": "Flavivirus",
"item": "https://questionsmedicales.fr/mesh/D005416"
},
{
"@type": "ListItem",
"position": 7,
"name": "Virus de la fièvre jaune",
"item": "https://questionsmedicales.fr/mesh/D015005"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Virus de la fièvre jaune - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Virus de la fièvre jaune",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Virus de la fièvre jaune",
"description": "Comment diagnostique-t-on la fièvre jaune ?\nQuels tests sont utilisés pour la fièvre jaune ?\nQuand faire un test pour la fièvre jaune ?\nPeut-on confondre la fièvre jaune avec d'autres maladies ?\nQuels sont les symptômes initiaux de la fièvre jaune ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Virus de la fièvre jaune",
"description": "Quels sont les symptômes de la fièvre jaune ?\nLa fièvre jaune cause-t-elle des saignements ?\nQuels signes indiquent une forme sévère ?\nCombien de temps durent les symptômes ?\nY a-t-il des symptômes spécifiques chez les enfants ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Virus de la fièvre jaune",
"description": "Comment prévenir la fièvre jaune ?\nQui doit se faire vacciner contre la fièvre jaune ?\nQuels sont les effets secondaires du vaccin ?\nComment éviter les piqûres de moustiques ?\nLe vaccin est-il efficace immédiatement ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Virus de la fièvre jaune",
"description": "Quel est le traitement de la fièvre jaune ?\nComment gérer la déshydratation due à la fièvre jaune ?\nDes médicaments peuvent-ils aider ?\nLa transfusion sanguine est-elle nécessaire ?\nPeut-on utiliser des antibiotiques pour la fièvre jaune ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Virus de la fièvre jaune",
"description": "Quelles sont les complications possibles de la fièvre jaune ?\nLa fièvre jaune peut-elle être mortelle ?\nQuels facteurs augmentent le risque de complications ?\nComment se manifeste l'insuffisance hépatique ?\nY a-t-il des séquelles après la fièvre jaune ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Virus de la fièvre jaune",
"description": "Qui est le plus à risque de contracter la fièvre jaune ?\nLes voyageurs doivent-ils se préoccuper de la fièvre jaune ?\nLes personnes non vaccinées sont-elles plus vulnérables ?\nLes enfants sont-ils plus à risque ?\nLes personnes âgées sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D015005?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la fièvre jaune ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sérologiques et PCR pour détecter le virus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la fièvre jaune ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques IgM et IgG ainsi que la PCR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quand faire un test pour la fièvre jaune ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests doivent être effectués dès l'apparition des symptômes, généralement dans les 7 jours."
}
},
{
"@type": "Question",
"name": "Peut-on confondre la fièvre jaune avec d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec la dengue ou le paludisme en raison de symptômes similaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes initiaux de la fièvre jaune ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes initiaux incluent fièvre, frissons, douleurs musculaires et céphalées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la fièvre jaune ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, douleurs musculaires, nausées, et jaunisse."
}
},
{
"@type": "Question",
"name": "La fièvre jaune cause-t-elle des saignements ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements peuvent survenir, notamment des saignements gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une forme sévère ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une jaunisse, des douleurs abdominales et des saignements sont des signes de gravité."
}
},
{
"@type": "Question",
"name": "Combien de temps durent les symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent durer de quelques jours à deux semaines, selon la gravité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques chez les enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants présentent des symptômes similaires, mais peuvent avoir des manifestations plus sévères."
}
},
{
"@type": "Question",
"name": "Comment prévenir la fièvre jaune ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination est la méthode la plus efficace pour prévenir la fièvre jaune."
}
},
{
"@type": "Question",
"name": "Qui doit se faire vacciner contre la fièvre jaune ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les voyageurs vers des zones à risque et les personnes vivant dans ces zones doivent se vacciner."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires du vaccin ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fièvre légère, douleurs au site d'injection, et fatigue."
}
},
{
"@type": "Question",
"name": "Comment éviter les piqûres de moustiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des répulsifs, portez des vêtements longs et installez des moustiquaires."
}
},
{
"@type": "Question",
"name": "Le vaccin est-il efficace immédiatement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le vaccin confère une protection après 10 jours, mais l'immunité dure plusieurs années."
}
},
{
"@type": "Question",
"name": "Quel est le traitement de la fièvre jaune ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement antiviral spécifique; le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment gérer la déshydratation due à la fièvre jaune ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hydratation par voie intraveineuse est essentielle pour traiter la déshydratation."
}
},
{
"@type": "Question",
"name": "Des médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analgésiques et antipyrétiques peuvent être utilisés pour soulager les symptômes."
}
},
{
"@type": "Question",
"name": "La transfusion sanguine est-elle nécessaire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une transfusion peut être nécessaire en cas de saignements sévères ou d'anémie."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des antibiotiques pour la fièvre jaune ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les antibiotiques ne sont pas efficaces contre les virus, y compris le virus de la fièvre jaune."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la fièvre jaune ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'insuffisance hépatique, les saignements et le choc."
}
},
{
"@type": "Question",
"name": "La fièvre jaune peut-elle être mortelle ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre jaune peut être mortelle, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies préexistantes et l'absence de vaccination augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'insuffisance hépatique ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par une jaunisse, des douleurs abdominales et des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des séquelles après la fièvre jaune ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines personnes peuvent avoir des séquelles hépatiques ou neurologiques après la maladie."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque de contracter la fièvre jaune ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes vivant ou voyageant dans des zones endémiques sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Les voyageurs doivent-ils se préoccuper de la fièvre jaune ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs vers des régions à risque doivent être vaccinés et informés."
}
},
{
"@type": "Question",
"name": "Les personnes non vaccinées sont-elles plus vulnérables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'absence de vaccination augmente considérablement le risque d'infection."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent être plus vulnérables aux complications graves de la fièvre jaune."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un risque accru de complications sévères liées à la fièvre jaune."
}
}
]
}
]
}
Hearing loss is the third leading global cause of disability and is associated with poorer quality of life. Hearing aids are often recommended for hearing loss; however, hearing aid uptake and use rat...
A multi-center, prospective, randomized patient-blind controlled trial with a pre- and post-tests design. New hearing aid users ≥ 18 years of age will be recruited from Vancouver, Canada. They will be...
This trial is designed to evaluate the efficacy of one-on-one MI in improving hearing aid use in new adult users in the short and long terms. Results will contribute to the evidence on whether MI coun...
ClinicalTrials.gov NCT04673565 . Registered on 17 December 2020....
Depression is a leading cause of disability worldwide, and treatments could be more effective. Identifying methods to improve treatment success has the potential to reduce disease burden dramatically....
The CBT + trial will be a parallel-arm randomized controlled trial that will recruit 40 adult participants with DSM-5 diagnosed depression (verified with clinical interview) via referrals, mass emails...
The novel approach of priming CBT with moderate-intensity aerobic exercise evaluated in a randomized controlled trial (CBT + trial) has the potential to demonstrate the usefulness of exercise as an au...
ClinicalTrials.gov NCT06001346 . Registered on August 21, 2023....
To better understand the explanatory-pragmatic distinction in the design and interpretation of randomized controlled trials (RCTs)....
We review the explanatory-pragmatic distinction in clinical trial design. We use the PRECIS-2 tool to evaluate the trial design of selected RCTs on percutaneous vertebroplasty for osteoporotic vertebr...
The selection of criteria and the scoring of multiple PRECIS domains were subjective and thus debatable. The pragmascope patterns of various vertebroplasty trials were heterogeneous. Many trials had b...
The results of a trial cannot be interpreted without understanding the various design choices made along the explanatory-pragmatic spectrum....
This proof-of-concept study retrospectively assessed the feasibility of applying a hybrid control arm design to a completed phase III randomized controlled trial (RCT; CheckMate-057) in advanced non-s...
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be ...
This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus...
Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated....
ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorit...
Allergic rhinitis (AR) is the inflammation of the membranes lining the nose due to allergen exposure and is characterized by sneezing, nasal congestion, itching of the nose, or postnasal discharge. Th...
The primary aim is to assess the efficacy of Ayurvedic management for AR (or vataja pratishyaya) by comparing it to a conventional control group. The secondary aims are to determine the mean change in...
This ongoing study is an open-label randomized controlled interventional trial, with a sample size of 90 both in the trial and standard control group (including dropouts, 20%), and will be carried out...
As of May 2024, 72 patients have been enrolled in both groups. Data analysis should be completed by February 2025. The study will be reported following standard guidelines for reporting randomized con...
The Ayurvedic approach could be an evidence-based therapeutic tactic for the management of AR....
Clinical Trials Registry India CTRI/2023/06/053395; https://tinyurl.com/564d2zz8....
DERR1-10.2196/56063....
Contemporary management of uncomplicated type B aortic dissections (uTBAD) is based on the acuity and various morphological features. Medical therapy is mandatory, while the risks of early thoracic en...
The trial is a randomized, open-label, superiority clinical trial with parallel assignment of subjects at 23 clinical sites in Denmark, Norway, Sweden, Finland, and Iceland. Eligibility includes patie...
This trial will evaluate the primary question of whether early TEVAR improves survival at 5 years among uTBAD patients. Moreover, the costs and the impact on quality of life should provide sorely need...
ClinicalTrials.gov NCT05215587. Registered on January 31, 2022....
With advances in antiretroviral therapy, people with HIV (PWH) are living longer and are less likely to die from AIDS-related complications. Yet, prior research has shown that smoking is often not add...
The current study is a type 1 hybrid effectiveness-implementation trial to evaluate the impact of a proactive, opt-out tobacco treatment intervention on cessation outcomes and advance understanding of...
This study will examine a novel approach to optimizing tobacco treatment delivery for PWH. Integrating effectiveness and implementation results will help define best practices for engaging PWH with ev...
ClinicalTrials.gov: NCT05019495 (August 24, 2021)....
Glaucoma is a chronic progressive optic neuropathy that necessitates lifelong treatment to reduce the decline of the optic nerve. Due to the extended and continuous treatments required for patients, c...
The primary objective of this study is to conduct a single-center randomized control trial involving patients with glaucoma. Acupuncture will be evaluated as an adjunctive therapy. The trial aims to e...
In this single-center randomized controlled trial, participants (N=50) with primary open-angle glaucoma will be randomly assigned to the treatment group, receiving ophthalmic acupuncture with "De Qi" ...
Recruitment of participants for the trial commenced on June 28, 2023. A total of 10 participants have been enrolled to test the feasibility of the experiment. We anticipate that the preliminary data f...
This trial uses rigorous methodology and comprehensive outcome measurements to assess the clinical efficacy of acupuncture as an adjunctive therapy for glaucoma, providing valuable insights for future...
ClinicalTrials.gov NCT05753137; https://clinicaltrials.gov/study/NCT05753137....
DERR1-10.2196/57888....
Investigators often conduct randomized controlled trials (RCTs) at multiple centers/sites when determining the effect of a treatment or an intervention. Diversifying recruitment across multiple instit...